Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'

Published 26/03/2024, 19:19
Updated 26/03/2024, 20:41
© Reuters. Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'

Benzinga - by Surbhi Jain, .

Shares of Krispy Kreme Inc (NASDAQ:DNUT) have surged following the company’s announcement of an expanded national partnership with McDonald's Corp (NYSE:MCD).

McDonald’s customers will now have the opportunity to purchase Krispy Kreme doughnuts at select McDonald's locations. These doughnuts will be available at all participating McDonald's outlets across the country by the end of 2026.

Krispy Kreme stock was up over 33% at the time of publication Tuesday.

Related: Why Doughnut Maker Krispy Kreme’s Shares Are Shooting Higher Today

Investors Turn To Insulin, As Burger-Doughnut Collab

Redditor DeltaPodcast took to r/wallstreetbets to post thoughts on the deal. The Redditor identified market catalysts and top stock picks, pursuant to the news, adding that “we’re about to cash in on the aftermath.”

Insulin stocks – Why they will spike following Mcdonalds – Krispy kreme collab

byu/DeltaPodcast inwallstreetbets

Market Catalysts

  • Sugar Surge: With the proliferation of sugary treats from McDonald’s and Krispy Kreme, concerns over diabetes and obesity are on the rise. This could translate to heightened demand for insulin products.
  • Global Epidemic: The global epidemic of obesity and diabetes extends beyond the United States alone; it affects populations worldwide. Therefore, insulin manufacturers with a global footprint are positioned to capitalize on this growing concern.

    • Redditor’s Top Healthcare Picks

  • Eli Lilly And Co (NYSE:LLY): A stalwart in the diabetes sector, Eli Lilly boasts a robust portfolio of insulin products. The news of the collaboration should ensure a steady revenue stream amid increasing demand.
  • Novo Nordisk A/S (NYSE:NVO): Renowned as the pioneer in insulin therapy, Novo Nordisk has a long-standing reputation for innovation and reliability, making it a solid investment choice in the face of heightened sugar consumption.
    • 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .
  • Sanofi SA (NASDAQ:SNY): With a strong presence in the diabetes market, Sanofi is well-equipped to navigate the surge in insulin demand, leveraging its extensive product offerings and global distribution network.

    • Image generated using artificial intelligence with Midjourney.

    © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Read the original article on Benzinga

    Latest comments

    Install Our App
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.